Working Memory Training on Delay Discounting Among Cigarette Smokers
CompletedNAResults postedLast updated 24 February 2025
What this trial tests
NA trial testing Working Memory Training + Behavioral Intervention in Tobacco Use Disorder/Cigarette Smoking in 13 participants. Completed in 30 June 2022.
18 and older, any sex, with Tobacco Use Disorder/Cigarette Smoking. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Delay DiscountingPrimary· Baseline, Post-treatment, 1 month follow up
Delay Discounting (DD) was measured via an established computerized binary choice task in which participants choose between an amount of money available immediately and larger amount of money available after a specified delay (1 day to 25 years). A computerized algorithm adjusts the immediately available reward across seven trials to determine an indifference point (k) for each amount/delay pairing. Indifference points are then used to calculate a rate of delay discounting for a $50, $200, $1,000 "larger later" sum. Larger scores mean greater delay discounting. While there is no strict minimum
Baseline
Group
Value
95% CI
Working Memory Training + Behavioral Intervention
-5.21
-12.12 – -0.19
Post-treatment
Group
Value
95% CI
Working Memory Training + Behavioral Intervention
-6.57
-10.66 – -4.24
1 month follow up
Group
Value
95% CI
Working Memory Training + Behavioral Intervention
-7.13
-10.19 – -4.15
Timeline Follow-Back (TLFB): Number of Total Cigarettes Smoked Per WeekPrimary· Baseline, Post-treatment, 1 month follow up
The Timeline Follow-Back (TLFB) for cigarette smoking is a self-report method used to assess an individual's smoking behavior over a specified period and specified as one week for this study. In this method, individuals are guided to recall their daily cigarette use by referencing events, routines, and cues that help them accurately track their smoking patterns. They are asked to document the number of cigarettes smoked each day, which provides a detailed, day-by-day account of their smoking habits. This data was then be summed to give a weekly total cigarettes smoked per week. The TLFB approa
Baseline
Group
Value
95% CI
Working Memory Training+ Behavioral Intervention
76.53
± 60.70
Post-treatment
Group
Value
95% CI
Working Memory Training+ Behavioral Intervention
38.83
± 40.15
1 month follow up
Group
Value
95% CI
Working Memory Training+ Behavioral Intervention
59.50
± 27.55
Carbon Monoxide LevelsPrimary· Baseline, Post-treatment, 1 month follow up
Participant reports of abstinence will be verified by expired carbon monoxide (\< 6 ppm cutoff for stated abstinence). CO levels are collected via a CO monitor.
Baseline
Group
Value
95% CI
Working Memory Training+ Behavioral Intervention
17.70
± 11.65
Post-treatment
Group
Value
95% CI
Working Memory Training+ Behavioral Intervention
17.67
± 9.44
1 month follow up
Group
Value
95% CI
Working Memory Training+ Behavioral Intervention
30
± 17.45
Working MemoryPrimary· Baseline, Post-treatment, 1 month follow up
Working memory was assessed by adding the scores of 3 different working memory measures: 1) the total achievement score in the Tower of Hanoi, 2) the total recall score of the Hopkins Verbal Learning Test- Revised and 3) the total scaled score of the Letter Number Sequencing. These measures are commonly used to assess working memory. In this study, the composite score of all measures ranged between 36 and 89 with higher scores representing greater working memory,
Baseline
Group
Value
95% CI
Working Memory Training+ Behavioral Intervention
58.61
± 14.43
Post-treatment
Group
Value
95% CI
Working Memory Training+ Behavioral Intervention
61.33
± 11.13
1 month follow up
Group
Value
95% CI
Working Memory Training+ Behavioral Intervention
71.25
± 13.42
Sponsor's own description
Despite widespread awareness of significant negative health consequences, cigarette smoking remains the leading cause of preventable morbidity and mortality in the US (Creamer et al., 2019; Jamal, 2018). Moreover, the highest rate of smoking and heaviest burden of smoking-related illness occurs among low-socioeconomic status (SES) individuals relative to higher SES groups (Businelle et al., 2010; Clegg et al., 2009). Low SES individuals are also 40% less likely to succeed in quitting smoking when they attempt to do so (National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health, 2014). One potential explanation for the disparity in rate of smoking and successful quit attempts may be differences in individual rates of delay discounting (DD), i.e., the degree to which rewards loses their value as the delays to their receipt increase (Odum, 2011). A proposed way to reduce steep DD and, potentially, substance use has been computer training for working memory, which has shown favorable results in a sample of individuals with stimulant dependence (Bickel et al., 2011) and substance use broadly (Felton et al., 2019), with the latter even showing decreases in cigarette smoking in a subset of the sample.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT06636214 — Adapting Changing Talk: Online (CHATO) to CHATO-Inclusive
· NA
· not yet recruiting
NCT07528963 — KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice
· NA
· enrolling by invitation
NCT07463755 — Low-Fidelity Driving Simulator Training in Parkinson's Disease.
· NA
· not yet recruiting
NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives
· NA
· recruiting
NCT07491510 — Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income
· NA
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Kansas Medical Center
Last refreshed: 24 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05210608.